ArticleCureus2025
A Rare Case of Small Lymphocytic Lymphoma (SLL) Arising After Chronic Myeloid Leukemia (CML) in a Single Patient.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic myeloid leukemia (CML) and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) are among the most common types of leukemia in adults. However, the sequential development of CLL/SLL following a prior diagnosis of CML in the same individual is exceedingly rare. We present the case of a 65-year-old male initially diagnosed with Philadelphia chromosome-positive CML, who subsequently developed SLL, the tissue-based counterpart of CLL. His CML was initially managed with bosutinib, later switched to dasatinib due to side effects, resulting in both cytogenic and molecular response. Two years later, he was diagnosed with SLL. This report explores the potential molecular mechanisms underlying the coexistence of these distinct hematologic malignancies and highlights important considerations in the selection of appropriate treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.